Description
Sofosbuvir400mg+Velpatasvir100mg
Each film-coated tablet contains: 400 mg of sofosbuvir and 100 mg of velpatasvir.
INDICATIONS
LuciSoVe is a fixed -dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection : • without cirrhosis or with compensated cirrhosis. • with decompensated cirrhosis for use in combination with ribavirin.
DOSAGE AND USE
• Recommended dosage in adults: One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily with or without food. • Recommended dosage in pediatric patients 3 years and older: Recommended dosage is based on weight. Refer to Table 2 of the full prescribing information for specific dosing guidelines based on body weight. • For pediatric patients less than 6 years of age, administer LuciSoVe oral pellets with food. • HCV/HIV-1 coinfection: For patients with HCV/HIV-1 coinfection, follow the dosage recommendations in the table 1 of the full prescribing information. • For treatment -naïve and treatment -experienced liver transplant recipients without cirrhosis or with compensated cirrhosis (Child Pugh A), the recommended regimen is LuciSoVe once daily for 12 weeks. • If used in combination with ribavirin, follow the recommendations for ribavirin dosing and dosage modifications.
STORAGE
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNINGS
Keep medicine out of reach of Children. Do not administer LuciSoVe during Pregnancy and Lactation
Reviews
There are no reviews yet.